AYTU BIOPHARMA, INC Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31)
AYTU BIOPHARMA, INC (AYTU) reported Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) of -$61.52 thousand for the 12-month period ending 2017-06-30, per its 10-K filed 2017-08-31.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 · last filed 2018-05-14
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $0.00.
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-03-31 was -$292.45K.
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2016-12-31 was -$497.16K.
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2016-09-30 was $728.10K.
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2017 was -$61.52K.
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2016 was -$971.63K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | -$292.45K derived: sum of 2 quarters · filed 2018-05-14 | -$789.62K derived: sum of 3 quarters · filed 2018-05-14 | -$61.52K 10-K · filed 2017-08-31 |
| 2017-03-31 | -$292.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | -$789.62K derived: sum of 2 quarters · filed 2018-05-14 | -$61.52K 10-Q · filed 2018-05-14 | -$1.03M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | -$497.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | $230.94K 10-Q · filed 2018-02-08 | -$740.69K derived: sum of 3 quarters · filed 2018-02-08 | |
| 2016-09-30 | $728.10K 10-Q · filed 2017-11-09 | -$243.53K derived: sum of 2 quarters · filed 2017-11-09 | ||
| 2016-06-30 | -$971.63K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | -$971.63K 10-K · filed 2017-08-31 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |